Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

被引：0
|
作者：
Kamal Chamoun
Hagop Kantarjian
Rami Atallah
Graciela Nogueras Gonzalez
Ghayas C. Issa
Mary Beth Rios
Guillermo Garcia-Manero
Gautam Borthakur
Farhad Ravandi
Nitin Jain
Naval Daver
Marina Konopleva
Courtney D. DiNardo
Tapan Kadia
Naveen Pemmaraju
Elias Jabbour
Jorge Cortes
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Leukemia
[2] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
来源：
Journal of Hematology & Oncology | / 12卷
关键词：
CML; TKI discontinuation; MR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA. EXPERIENCE IN A CENTER
    Navarro-Almenzar, Begona
    Perez, Lopez Raul
    Fernandez, Poveda Elena
    Leal, Rubio Juan Diego
    Sanchez, Villalobos Maria
    Serrano, Jara Claudia
    HAEMATOLOGICA, 2020, 105 : 394 - 395
  • [22] What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?
    Harrington, Patrick
    Radia, Deepti
    de Lavallade, Hugues
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) : 213 - 222
  • [23] Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
    Ureshino, Hiroshi
    Kamachi, Kazuharu
    Sano, Haruhiko
    Okamoto, Sho
    Itamura, Hidekazu
    Yoshimura, Mariko
    Katsuya, Hiroo
    Ando, Toshihiko
    Kimura, Shinya
    HEMATOLOGY, 2022, 27 (01) : 1171 - 1175
  • [24] Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
    Mario Tiribelli
    Ahmet Emre Eskazan
    Oncology and Therapy, 2019, 7 : 95 - 100
  • [25] Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
    Tiribelli, Mario
    Eskazan, Ahmet Emre
    ONCOLOGY AND THERAPY, 2019, 7 (02) : 95 - 100
  • [26] Role of Folate Receptor 3 in Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia
    Shen, Na
    Zhu, Xiaojian
    Zhou, Shu
    You, Yong
    Zhong, Zhaodong
    Zhu, Xiaoying
    Li, Qing
    Zou, Ping
    Zhang, Yicheng
    BLOOD, 2018, 132
  • [27] Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
    Inzoli, Elena
    Aroldi, Andrea
    Piazza, Rocco
    Gambacorti-Passerini, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : 1075 - 1085
  • [28] Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
    Robin, J. B.
    Theron, A.
    Quittet, P.
    Exbrayat, C.
    Gaillard, J. B.
    Lavabre-Bertrand, T.
    David, S.
    Saad, A.
    Jourdan, E.
    Cartron, G.
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 1015 - 1022
  • [29] Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
    J. B. Robin
    A. Theron
    P. Quittet
    C. Exbrayat
    J. B. Gaillard
    T. Lavabre-Bertrand
    S. David
    A. Saad
    E. Jourdan
    G. Cartron
    Annals of Hematology, 2022, 101 : 1015 - 1022
  • [30] Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield
    Dvorak, P.
    Lysak, D.
    Vokurka, S.
    NEOPLASMA, 2015, 62 (02) : 167 - 171
12345